ACHIEVE-1 is a phase 3 trial, which evaluated the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes and inadequate glycemic control with diet and exercise alone.

Candidates can complete the registrations for phase 3 through the official website- dost.cgg.gov.in. As per the schedule, the deadline to apply for the TSCHE DOST 2025 admission through web options is ...

SAN DIEGO, June 20, 2025--Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company today announced the Tandem t:slim X2™ insulin pump with Control ...

Bayer has added another phase 3 trial into its registration programme for oral Factor XIa inhibitor asundexian, signalling growing confidence in a drug that generated mixed results in phase 2.

UCB and Biogen say their first phase 3 trial of their systemic lupus erythematosus (SLE) candidate dapirolizumab pegol was a success, and a second is now expected to start before the end of the year.

While the usual $1.50 fare is the cheapest option for most people in need of a ride, 'Dump The Pump' Day allows riders to skip worrying about having enough money for every trip.

In the randomised phase 3 TRIBE study, 1 first-line treatment of patients with metastatic colorectal cancer with FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab ...